Deepika polineni.

Europe PMC is an archive of life sciences journal literature.Elexacaftor–tezacaftor–ivacaftor was efficacious in patients with cystic fibrosis with Phe508del–minimal function genotypes, in whom previous CFTR modulator regimens were ineffective ...Polineni D, Dang H, Gallins PJ, Jones LC, Pace RG, Stonebraker JR, et al. Airway mucosal host defense is key to genomic regulation of cystic fibrosis lung disease severity. Am J Respir Crit Care Med. 2018; 197:79-93. [PMC free article] [Google Scholar]Garlow GM, Gettle LS, Felicetti NJ, Polineni D, Gifford AH. Perspectives on anemia and iron deficiency from the cystic fibrosis care community . Pediatric Pulmonology . 2019 Jul;54(7):939-940. doi: 10.1002/ppul.24323Deepika Polineni and Leland Graves III contributed equally as senior authors. * A. Anabtawi [email protected] 1 Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Kansas Medical Center, 3901 Rainbow Blvd., Mail stop

William B. Hannah's 26 research works with 563 citations and 1,609 reads, including: The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database ...Deepika Polineni, MD, MPH. Associate Professor of Pediatrics, Allergy and Pulmonary Medicine Director, Cystic Fibrosis CenterHEALTH OUTCOMES ASSEMBLY: RACIAL AND ETHNIC DISPARITIES . Friday, August 27, 2021 | 9 a.m.-12:30 p.m. Presented by . KU Medical Center Office for Diversity, Equity ...

Deepika Polineni, MD/. Ricardo A. Mosquera, MD. Sarcoidosis. Robert Baughman, MD,. PhD/ W. Ennis James,. MD/ Connie Hsia, MD/. Haala Rokadia, MD/. Yolanda ...Alex H Gifford # 1 , Deepika Polineni # 2 , Jianghua He 3 , Jessica L D'Amico 4 , Dana B Dorman 5 , Molly A Williams 5 , Amanda B Nymon 6 , Akshu Balwan 7 , Theodore Budden 8 , Jonathan B Zuckerman 4 Affiliations 1 Section of Pulmonary Medicine, 5C, Dartmouth-Hitchcock Medical Center ...

Cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. Mutations in CFTR, the gene encoding the epithelial ion channel that normally transports chloride and bicarbonate, lead to impaired mucus hydration and clearance. Classical cystic fibrosis is thus characte …NHLBI in planning collaboration with NIDDK, NIAID and the Cystic Fibrosis Foundation is hosting a virtual workshop in June to bring together experts in Cystic Fibrosis (CF) clinical-translational research to address critical questions and inform the field of the future research needs in the era of highly effective modulator therapies (HEMT) for the treatment of CF.Deepika Polineni 3, G Alexander Patterson 3, Reto A Schwendener 4, John D Allard 5, Gary Peltz 5 & … Michael J Holtzman 1,6 Show authors. Nature Medicine volume 14, pages 633–640 (2008)Cite ...A few months and a global pandemic later, he's partnered with pulmonologist Deepika Polineni, MD, MPH, associate professor in the KU School of Medicine, and they have launched a trial together exploring a drug to fight COVID-19. ... Gan reached out to Polineni to partner as co-investigator. Together, the two researchers reached out to Aclaris ...

Deepika Polineni, MD, MPH. Associate Professor of Pediatrics, Allergy and Pulmonary Medicine. Director, Cystic Fibrosis Center. Click to see this content.

elevated in patients with IPF, and the higher the burden, the more rapid the disease progression (2). Using droplet digital PCR, a more sensitive and accurate measure than traditional

Matthias Griese, Stefano Costa, Rachel W. Linnemann, Marcus A. Mall, Edward F. McKone, Deepika Polineni, Bradley S. Quon, Felix C. Ringshausen, Jennifer L. Taylor ...The University of Kansas Medical Center announced today a trial exploring a drug intended to fight the cytokine storm common in COVID-19.Overall, studies demonstrated that inhaled aztreonam is a safe and effective antimicrobial treatment for the eradication of newly acquired P. aeruginosa and long-term suppressive therapy of chronic endobronchial infection among people with cystic fibrosis. Keywords: Cystic fibrosis, aztreonam lysine, inhalation, Pseudomonas.Deepika Polineni, Stephanie D Davis, Sharon D Dell. Paediatric Respiratory Reviews 2016 March. Primary Ciliary Dyskinesia (PCD) is a rare heterogenic disorder leading to significant respiratory morbidity. Health-care providers who treat PCD must familiarize themselves with recommended treatment strategies. However, most of the treatments ...Cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. Mutations in CFTR, the gene encoding the epithelial ion cha...

Semantic Scholar profile for Deepika Polineni, with 3 scientific research papers. Skip to search form Skip to main content Skip to account menu. Semantic Scholar's Logo. Search 214,242,884 papers from all fields of science. Search. Sign In Create …Dive into the research topics where Deepika Polineni is active. These topic labels come from the works of this person. Together they form a unique fingerprint. 1 Similar Profiles; Cystic Fibrosis Medicine & Life Sciences 100%. Lung Diseases Medicine & Life Sciences 26%. tezacaftor ...BACKGROUND: Elexacaftor-tezacaftor-ivacaftor is a small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen shown to be efficacious in patients wCystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. Mutations in CFTR, the gene encoding the epithelial ion channel that normally transports chloride and bicarbonate, lead to impaired mucus hydration and clearance. Classical cystic fibrosis is thus characterised by chronic pulmonary infection and inflammation, pancreatic exocrine insufficiency, male ...Integrative Transcriptomic and Genomic Analysis Reveals Gene Networks Associated with Cystic Fibrosis Lung Disease Severity

Elexacaftor–tezacaftor–ivacaftor was efficacious in patients with cystic fibrosis with Phe508del–minimal function genotypes, in whom previous CFTR modulator regimens were ineffective ...

Dr. Lucas Pitts is a pulmonologist in Kansas City, KS and is affiliated with The University of Kansas Hospital. He received his medical degree from University of Kansas School of Medicine and has been in practice 12 years. He specializes in pleural disease.Garlow, M.S., R.D., L.D.N., C.N.S.C.,1 Lucy S. Gettle, R.D.N., C.N.S.C.,2 Nicola J. Felicetti, R.N., B.S., M.S.N.,3 Deepika Polineni, M.D., M.P.H., ...Stimulation of inducible nitric oxide synthase in rat liver by hyaluronan fragments. Don C. Rockey, John J. Chung, Charlotte M. McKee, Paul W. Noble> ;Hepatology. 1998 Jan 1. 235 citations. Hyaluronan Fragments Induce Nitric-oxide Synthase in Murine Macrophages through a Nuclear Factor κB-dependent Mechanism *.Physician-scientists Gregory Gan and Deepika Polineni, who research cancer and cystic fibrosis, have teamed up to test a new drug with the potential to keep COVID-19 patients from needing a ventilator.Abstract. Cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. Mutations in CFTR, the gene encoding the epithelial ion channel that normally transports chloride and bicarbonate, lead to impaired mucus hydration and clearance. Classical cystic fibrosis is thus characterised by chronic pulmonary infection ...Gan reached out to Dr. Deepika Polineni, associate professor at the KU School of Medicine focused on cystic fibrosis research, to see if this drug can benefit coronavirus patients with worsening ...KU Medical Center was one of the sites of a phase 3 trial that led to the approval of the drug, known by its brand name, Trikafta, by the U.S. Food and Drug Administration on October 21.Search life-sciences literature (41,644,047 articles, preprints and more) Search. Advanced searchDeepika Polineni, MD; Margaret A. Pisani, MD, MPH; Ghada Bourjeily, MD; Marilyn K. Glassberg, MD; and Carolyn D’Ambrosio, MD There is now ample evidence that differences in sex and gender contribute to the incidence, susceptibility, presentation, diagnosis, and clinical course of many lung diseases. Some con-ComplicationsandPracticeVariationinthe UseofPeripherallyInsertedCentralVenous Catheters in People With Cystic Fibrosis The Prospective Study of Peripherally Inserted ...

About DR. DEEPIKA POLINENI MD. Deepika Polineni is a pediatrician established in Saint Louis, Missouri and her medical specialization is Pediatrics with a focus in pediatric allergy/immunology . The healthcare provider is registered in the NPI registry with number 1043332265 assigned on April 2007. The practitioner's primary taxonomy code is 2080P0201X with license number 2022004127 (MO).

Doctor Address. Children's Hospital Of Philadelphia - Pulmonology. 3401 Civic Center Blvd, Philadelphia, PA, 19104. (215) 590-3749.

Deepika Polineni, MD/ Ricardo A. Mosquera, MD Sarcoidosis Robert Baughman, MD, PhD/ W. Ennis James, MD/ Connie Hsia, MD/ Haala Rokadia, MD/ Yolanda Mageto, MD, chILD MPH/Lisa Maier, MD Robin Deterding, MD LAM/Tuberous Sclerosis Complex Carlos Girod, MD Lung Transplant John Reynolds, MD Pulmonary Fibrosis Susan K. Mathai, MD/ Traci Adams, MDAbstract. Cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. Mutations in CFTR, the gene encoding the epithelial ion channel that normally transports chloride and bicarbonate, lead to impaired mucus hydration and clearance. Classical cystic fibrosis is thus characterised by chronic pulmonary infection ...Doctor Address. 1500 E Med Center Dr 3920 Taubman, Ann Arbor, MI, 48109. (734) 763-9077. Affiliated Hospitals. 1. University of Michigan Health-Ann Arbor.Adam J. Shapiro, 1 Maureen Josephson, 2 Margaret Rosenfeld, 3 Ozge Yilmaz, 4 Stephanie D. Davis, 5 Deepika Polineni, 6 Elena Guadagno, 7 Margaret W. Leigh, 8 and Valery Lavergne 9 Adam J. Shapiro 1 Division of Pediatric Respiratory Medicine, Montreal Children's Hospital, McGill University Health Centre Research Institute, Montreal, Quebec, CanadaAmik Sodhi, Katherine Cox-Flaherty, Meredith Kendall Greer, Tasnim I Lat, Yuqing Gao, Deepika Polineni, Margaret A Pisani, Ghada Bourjeily, Marilyn K Glassberg, Carolyn D'Ambrosio.Methods We conducted a phase 3, randomized, double-blind, placebo-controlled trial to confirm the efficacy and safety of elexacaftor-tezacaftor-ivacaftor in patients 12 years of age or older with cystic fibrosis with Phe508del-minimal function genotypes. Patients were randomly assigned to receive elexacaftor-tezacaftor-ivacaftor or placebo for ...This webpage represents 1043332265 NPI record. The 1043332265 NPI number is assigned to the healthcare provider DEEPIKA POLINENI M.D., practice location address at 64 E 54TH ST KANSAS CITY, MO, 64112-2860. NPI record contains FOIA-disclosable NPPES health care provider information.Dr. Deepika Polineni, MD, is an Internal Medicine specialist practicing in Kansas City, KS with 19 years of experience. This provider currently accepts 40 insurance plans including Medicaid. New patients are welcome. Hospital affiliations include University Of Kansas Health Sytem.

Intro CF Foundation | Ask a Researcher: Dr. Deepika Polineni Cystic Fibrosis Foundation 12.2K subscribers 532 views 4 years ago Deepika Polineni, MD, MPH, an assistant professor of medicine and...Dr. Deepika Polineni is a pulmonologist in Kansas City, Kansas and is affiliated with University of Kansas Hospital.She received her medical degree from University of Missouri-Kansas City School ...Deepika Polineni MD. Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA. Contribution: Resources (equal), Supervision (supporting), Writing - review & editing (supporting) Search for more papers by this authorInstagram:https://instagram. rh wilsonstar nails pompano beachgreg heiar.kaitlyn moore Cystic Fibrosis Revisited - a Review Study. 2017;13 (2):102-109. doi: 10.2174/1573406412666160608113235. Michal Novotny Petra Maresova. 27292156. 10.2174/1573406412666160608113235. Cystic fibrosis (CF) is an incurable, chronic disease, which causes severe damages to respiratory and digestive tracts. It is the most common … bill kansassupply chain management degree jobs This webpage represents 1043332265 NPI record. The 1043332265 NPI number is assigned to the healthcare provider DEEPIKA POLINENI M.D., practice location address at 64 E 54TH ST KANSAS CITY, MO, 64112-2860. NPI record contains FOIA-disclosable NPPES health care provider information.Deepika Polineni, M.D., MPH, assistant professor of internal medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at KU Medical Center, and a pulmonolo-gist at the cystic fibrosis clinic for The University of Kansas Health System, is a co-author on the study. Cystic fibrosis is a progressive 9pm pst to india time Michal Shteinberg, Iram J. Haq, Deepika Polineni, Jane C. Davies. Division of Allergy & Pulmonary Medicine; Research output: Contribution to journal › Review article › peer-review. 128 Scopus citations. Overview; Fingerprint; Abstract. Cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. Mutations ...Abstract. Patients with cystic fibrosis have increased risk of pulmonary infections, and reducing spread of microorganisms is critical. To improve hospital-staff adherence to infection control guidelines, we implemented brightly colored Safe Zone floor decals, staff compliance contracts, and an infection control in-service video.